Carisma Therapeutics (NASDAQ:CARM) Downgraded by BTIG Research to “Neutral”

BTIG Research lowered shares of Carisma Therapeutics (NASDAQ:CARM) from a buy rating to a neutral rating in a research note published on Tuesday, MarketBeat reports.

Other equities analysts have also issued reports about the stock. D. Boral Capital dropped their price objective on shares of Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday. HC Wainwright cut their price objective on shares of Carisma Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, November 25th. Finally, EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th.

Carisma Therapeutics Trading Down 11.4 %

Carisma Therapeutics stock opened at $0.69 on Tuesday. The stock has a 50-day simple moving average of $0.93 and a 200 day simple moving average of $1.05. The stock has a market capitalization of $28.92 million, a P/E ratio of -0.44 and a beta of 1.44. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. Carisma Therapeutics has a 52 week low of $0.63 and a 52 week high of $3.16.

Carisma Therapeutics (NASDAQ:CARM) last issued its earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31). Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. The company had revenue of $3.39 million during the quarter. Analysts expect that Carisma Therapeutics will post -1.32 earnings per share for the current year.

Institutional Trading of Carisma Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Carisma Therapeutics by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after purchasing an additional 11,200 shares during the period. Barclays PLC increased its stake in Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares during the period. Wexford Capital LP raised its holdings in Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Carisma Therapeutics during the 2nd quarter valued at $40,000. Institutional investors and hedge funds own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.